Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry’s Lesson On Non-Inferiority Margins In Anti-Infective Trials: Use 10%

Executive Summary

If industry is to learn anything from the three-day Anti-Infective Drugs Advisory Committee meeting on how to correctly use non-inferiority margins in trials, it is to adhere to the panel's recommendation of 10 percent (at least for now)

You may also be interested in...



FDA Emphasizes Pathogen ID In Complicated Intra-Abdominal Infection Guidance

The agency checked another box on the list of guidances anticipated by developers of antibiotic drugs with the Oct. 1 release of a draft guidance on treatments for complicated intra-abdominal infections.

PhRMA Urges FDA To Set Non-Inferiority Margin For Skin Infection Drugs

FDA should provide more specificity on the non-inferiority margin it expects clinical trials for acute bacterial skin and skin structure infection (ABSSSI) treatments to satisfy, pharmaceutical companies and infectious disease specialists say.

PhRMA Urges FDA To Set Non-Inferiority Margin For Skin Infection Drugs

FDA should provide more specificity on the non-inferiority margin it expects clinical trials for acute bacterial skin and skin structure infection (ABSSSI) treatments to satisfy, pharmaceutical companies and infectious disease specialists say.

Related Content

Latest News
UsernamePublicRestriction

Register

PS050369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel